Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference ACN Newswire - Mon Aug 24, 10:59AM CDT

Public Healthcare Companies Meet Institutional Investors at the 5th Annual ROTH Healthcare Opportunities Conference

CING : 5.68 (+2.34%)
SER : 2.63 (-8.36%)
GANX : 2.00 (-0.25%)
BIOA : 9.38 (-1.05%)
OSTX : 1.5500 (-2.52%)
VTVT : 33.89 (+1.91%)
MASS : 10.92 (+2.25%)
PYPD : 4.99 (-2.25%)
TKNO : 7.34 (-0.27%)
OVID : 2.82 (+0.71%)
MDCX : 0.2574 (-5.30%)
EQ : 2.20 (-4.76%)
NeuroSense Issues CEO Letter to Shareholders PR Newswire - Thu Aug 13, 8:30AM CDT

CAMBRIDGE, Mass. , Aug. 13, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSN : 0.3750 (-0.35%)
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire - Thu Aug 6, 10:29AM CDT

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission

NRSN : 0.3750 (-0.35%)
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PR Newswire - Wed Jul 22, 7:30AM CDT

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire - Mon Jul 6, 7:45AM CDT

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PR Newswire - Mon Jun 29, 8:30AM CDT

CAMBRIDGE, Mass. , June 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire - Thu Jun 25, 8:20AM CDT

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement

NRSN : 0.3750 (-0.35%)
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire - Mon Jun 22, 8:00AM CDT

CAMBRIDGE, Mass. , June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PR Newswire - Thu Jun 11, 8:00AM CDT

CAMBRIDGE, Mass. , June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel...

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PR Newswire - Tue Jun 9, 8:00AM CDT

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents

NRSNW : 0.0392 (-12.11%)
NRSN : 0.3750 (-0.35%)

Barchart Exclusives

Treasuries Have Reclaimed the Yield Crown From Dividend Stocks. Here’s How Income Investors Can Adapt. Barchart - Mon Aug 24, 6:30PM CDT
Treasuries have reclaimed the yield advantage, with fewer than 4% of S&P 500 stocks now yielding more than the 10-year Treasury (near 4.69%), compared with nearly 63% a decade ago. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.